Silexion Therapeutics (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
$2.12
-$0.10(-4.76%)
At close: 4:00 PM EST
$2.12
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$1.07 - $22.36
Previous CloseN/A
Volume52.80K
Average Volume (3M)50.14K
Market Cap
$4.03M
Enterprise Value-$4.84M
Total Cash (Recent Filing)$5.99M
Total Debt (Recent Filing)$468.00K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
May 19, 2026EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.38
Shares Outstanding3,330,785
10 Day Avg. Volume60,134
30 Day Avg. Volume50,136
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit484.42
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$6.00Price Target Upside183.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignA Phase 2/3 protocol with a safety run-in, randomized controlled expansion, and interim analysis improves the ability to select an effective dose and demonstrate meaningful survival benefit.
Preclinical EvidencePreclinical data showing pan-KRAS inhibition and systemic anti-tumor activity strengthen the scientific rationale for SIL-204 as a potential treatment for hard-to-treat pancreatic tumors.
Regulatory MilestoneIsraeli regulatory clearance to initiate a Phase 2/3 trial for SIL-204 advances clinical development for locally advanced pancreatic cancer and reduces uncertainty around next-stage testing.
Bears Say
Development And Commercial RiskAnalyst valuation explicitly factors development, regulatory, and commercial risks, signaling that setbacks in trials or approval could materially reduce expected revenues.
Funding RiskExisting cash supports initiation of the Phase 2/3 study but the likely need for additional financing to complete development could lead to dilution or delays that pressure the stock.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $1.07 and its highest was $22.36 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $4.03M.
When is Silexion Therapeutics’s upcoming earnings report date?
Silexion Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 44 days.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on Mar 24, 2026. The company reported -$2.385 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$1.265.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate is -1.29.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 3,330,785 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$2.385 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went up 5.97%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
$6.00
▲(183.02% Upside)